Israeli generic drugmaker Teva Pharmaceutical Industries Ltd. will buy its U.S. rival Barr Pharmaceuticals Inc. for $8.9 billion, in cash, stock and the assumption of debt, it said Friday.

Barr shareholders will receive $39.90 in cash and 0.6272 of an American depositary receipt of Teva, valuing each Barr share at $66.50.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]